Exelixis, Inc. (0IJO.L)
USD 35.26
(4.97%)
USD 35.26
(4.97%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.94 Billion USD | -4.2% |
| 2022 | 3.07 Billion USD | 17.4% |
| 2021 | 2.61 Billion USD | 22.41% |
| 2020 | 2.13 Billion USD | 13.35% |
| 2019 | 1.88 Billion USD | 32.58% |
| 2018 | 1.42 Billion USD | 117.05% |
| 2017 | 655.29 Million USD | 9.67% |
| 2016 | 597.54 Million USD | 79.8% |
| 2015 | 332.34 Million USD | 1.34% |
| 2014 | 327.96 Million USD | -34.84% |
| 2013 | 503.28 Million USD | -30.21% |
| 2012 | 721.09 Million USD | 83.36% |
| 2011 | 393.26 Million USD | 9.0% |
| 2010 | 360.79 Million USD | 5.06% |
| 2009 | 343.41 Million USD | -14.49% |
| 2008 | 401.62 Million USD | -2.55% |
| 2007 | 412.12 Million USD | 4.22% |
| 2006 | 395.41 Million USD | 18.85% |
| 2005 | 332.71 Million USD | 14.2% |
| 2004 | 291.34 Million USD | -18.57% |
| 2003 | 357.79 Million USD | 5.51% |
| 2002 | 339.11 Million USD | -2.16% |
| 2001 | 346.61 Million USD | 69.15% |
| 2000 | 204.91 Million USD | 984.2% |
| 1999 | 18.9 Million USD | 110.44% |
| 1998 | 8.98 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 2.77 Billion USD | -1.09% |
| 2024 Q3 | 2.96 Billion USD | 6.75% |
| 2024 Q1 | 2.8 Billion USD | -4.71% |
| 2023 Q3 | 2.97 Billion USD | -5.27% |
| 2023 FY | 2.94 Billion USD | -4.2% |
| 2023 Q1 | 3.14 Billion USD | 2.34% |
| 2023 Q2 | 3.14 Billion USD | -0.03% |
| 2023 Q4 | 2.94 Billion USD | -1.16% |
| 2022 Q3 | 2.96 Billion USD | 2.78% |
| 2022 Q2 | 2.88 Billion USD | 8.56% |
| 2022 FY | 3.07 Billion USD | 17.4% |
| 2022 Q1 | 2.65 Billion USD | 1.45% |
| 2022 Q4 | 3.07 Billion USD | 3.72% |
| 2021 Q2 | 2.36 Billion USD | 8.07% |
| 2021 Q1 | 2.19 Billion USD | 2.49% |
| 2021 FY | 2.61 Billion USD | 22.41% |
| 2021 Q4 | 2.61 Billion USD | 6.88% |
| 2021 Q3 | 2.44 Billion USD | 3.4% |
| 2020 Q4 | 2.13 Billion USD | 1.25% |
| 2020 Q1 | 1.95 Billion USD | 3.71% |
| 2020 Q2 | 2.04 Billion USD | 4.65% |
| 2020 Q3 | 2.11 Billion USD | 3.15% |
| 2020 FY | 2.13 Billion USD | 13.35% |
| 2019 Q1 | 1.54 Billion USD | 8.4% |
| 2019 FY | 1.88 Billion USD | 32.58% |
| 2019 Q4 | 1.88 Billion USD | 5.65% |
| 2019 Q3 | 1.78 Billion USD | 8.63% |
| 2019 Q2 | 1.64 Billion USD | 6.57% |
| 2018 Q4 | 1.42 Billion USD | 38.85% |
| 2018 Q1 | 774.91 Million USD | 18.25% |
| 2018 Q3 | 1.02 Billion USD | 12.42% |
| 2018 FY | 1.42 Billion USD | 117.05% |
| 2018 Q2 | 911.15 Million USD | 17.58% |
| 2017 Q3 | 609.77 Million USD | 18.05% |
| 2017 Q4 | 655.29 Million USD | 7.47% |
| 2017 Q2 | 516.53 Million USD | -12.0% |
| 2017 Q1 | 586.98 Million USD | -1.77% |
| 2017 FY | 655.29 Million USD | 9.67% |
| 2016 Q2 | 477.13 Million USD | -3.13% |
| 2016 Q4 | 597.54 Million USD | 8.94% |
| 2016 Q1 | 492.53 Million USD | 48.2% |
| 2016 Q3 | 548.49 Million USD | 14.95% |
| 2016 FY | 597.54 Million USD | 79.8% |
| 2015 Q1 | 282.93 Million USD | -13.73% |
| 2015 FY | 332.34 Million USD | 1.34% |
| 2015 Q4 | 332.34 Million USD | -8.51% |
| 2015 Q3 | 363.24 Million USD | 46.01% |
| 2015 Q2 | 248.77 Million USD | -12.07% |
| 2014 Q1 | 497.56 Million USD | -1.14% |
| 2014 Q3 | 383.65 Million USD | -12.93% |
| 2014 Q2 | 440.63 Million USD | -11.44% |
| 2014 FY | 327.96 Million USD | -34.84% |
| 2014 Q4 | 327.96 Million USD | -14.52% |
| 2013 Q1 | 659.52 Million USD | -8.54% |
| 2013 Q4 | 503.28 Million USD | -9.47% |
| 2013 Q3 | 555.95 Million USD | -9.17% |
| 2013 Q2 | 612.08 Million USD | -7.19% |
| 2013 FY | 503.28 Million USD | -30.21% |
| 2012 Q2 | 374.48 Million USD | -9.24% |
| 2012 Q3 | 762.61 Million USD | 103.64% |
| 2012 FY | 721.09 Million USD | 83.36% |
| 2012 Q4 | 721.09 Million USD | -5.44% |
| 2012 Q1 | 412.6 Million USD | 4.92% |
| 2011 FY | 393.26 Million USD | 9.0% |
| 2011 Q3 | 411.63 Million USD | -9.37% |
| 2011 Q4 | 393.26 Million USD | -4.46% |
| 2011 Q2 | 454.18 Million USD | -8.38% |
| 2011 Q1 | 495.73 Million USD | 37.4% |
| 2010 Q3 | 372.9 Million USD | -11.15% |
| 2010 Q1 | 284.22 Million USD | -17.24% |
| 2010 Q2 | 419.72 Million USD | 47.68% |
| 2010 Q4 | 360.79 Million USD | -3.25% |
| 2010 FY | 360.79 Million USD | 5.06% |
| 2009 Q1 | 355.1 Million USD | -11.58% |
| 2009 Q2 | 333.17 Million USD | -6.18% |
| 2009 Q3 | 421.1 Million USD | 26.39% |
| 2009 Q4 | 343.41 Million USD | -18.45% |
| 2009 FY | 343.41 Million USD | -14.49% |
| 2008 Q1 | 370.57 Million USD | -10.08% |
| 2008 FY | 401.62 Million USD | -2.55% |
| 2008 Q4 | 401.62 Million USD | 57.65% |
| 2008 Q3 | 254.76 Million USD | -19.54% |
| 2008 Q2 | 316.62 Million USD | -14.56% |
| 2007 Q1 | 420.63 Million USD | 6.38% |
| 2007 Q4 | 412.12 Million USD | -1.94% |
| 2007 Q3 | 420.29 Million USD | 13.05% |
| 2007 FY | 412.12 Million USD | 4.22% |
| 2007 Q2 | 371.78 Million USD | -11.61% |
| 2006 Q4 | 395.41 Million USD | 46.1% |
| 2006 Q1 | 337.58 Million USD | 1.46% |
| 2006 Q3 | 270.65 Million USD | -11.69% |
| 2006 Q2 | 306.47 Million USD | -9.21% |
| 2006 FY | 395.41 Million USD | 18.85% |
| 2005 Q4 | 332.71 Million USD | -1.77% |
| 2005 Q1 | 269.75 Million USD | -7.41% |
| 2005 FY | 332.71 Million USD | 14.2% |
| 2005 Q3 | 338.7 Million USD | 4.17% |
| 2005 Q2 | 325.14 Million USD | 20.53% |
| 2004 FY | 291.34 Million USD | -18.57% |
| 2004 Q1 | 321.65 Million USD | -10.1% |
| 2004 Q2 | 287.19 Million USD | -10.71% |
| 2004 Q3 | 267.86 Million USD | -6.73% |
| 2004 Q4 | 291.34 Million USD | 8.76% |
| 2003 Q3 | 336.82 Million USD | -6.24% |
| 2003 FY | 357.79 Million USD | 5.51% |
| 2003 Q2 | 359.23 Million USD | 11.97% |
| 2003 Q1 | 320.82 Million USD | -5.39% |
| 2003 Q4 | 357.79 Million USD | 6.23% |
| 2002 Q2 | 298.36 Million USD | -7.03% |
| 2002 FY | 339.11 Million USD | -2.16% |
| 2002 Q1 | 320.93 Million USD | -7.41% |
| 2002 Q3 | 279.3 Million USD | -6.39% |
| 2002 Q4 | 339.11 Million USD | 21.41% |
| 2001 Q1 | 196.05 Million USD | -4.32% |
| 2001 Q3 | 246.71 Million USD | 3.44% |
| 2001 Q4 | 346.61 Million USD | 40.49% |
| 2001 FY | 346.61 Million USD | 69.15% |
| 2001 Q2 | 238.51 Million USD | 21.66% |
| 2000 Q3 | 144.38 Million USD | -1.7% |
| 2000 Q4 | 204.91 Million USD | 41.92% |
| 2000 FY | 204.91 Million USD | 984.2% |
| 2000 Q1 | 29.39 Million USD | 0.0% |
| 2000 Q2 | 146.88 Million USD | 399.68% |
| 1999 FY | 18.9 Million USD | 110.44% |
| 1998 FY | 8.98 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | -253.781% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -213.979% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -278.253% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -1677.816% |
| bluebird bio, Inc. | 619.16 Million USD | -375.217% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -2238.099% |
| Imunon, Inc. | 21.91 Million USD | -13324.344% |
| Editas Medicine, Inc. | 499.15 Million USD | -489.47% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 88.972% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 12.314% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -145.462% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 9.505% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -108.829% |
| Verastem, Inc. | 149.71 Million USD | -1865.266% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 96.369% |
| Waters Corporation | 4.62 Billion USD | 36.407% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 97.02% |
| Biogen Inc. | 26.84 Billion USD | 89.039% |
| Nektar Therapeutics | 398.03 Million USD | -639.224% |
| Perrigo Company plc | 10.8 Billion USD | 72.779% |
| Dynavax Technologies Corporation | 997.09 Million USD | -195.093% |
| Illumina, Inc. | 10.11 Billion USD | 70.899% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -10307.174% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -277.056% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -1222.372% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -4379.155% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 56.993% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -1679.795% |
| Evolus, Inc. | 188.99 Million USD | -1456.819% |
| Adicet Bio, Inc. | 207.29 Million USD | -1319.406% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -1390.518% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 91.105% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -1329.745% |
| FibroGen, Inc. | 423.52 Million USD | -594.724% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 72.662% |
| OPKO Health, Inc. | 2.01 Billion USD | -46.262% |
| Homology Medicines, Inc. | 47.05 Million USD | -6152.751% |
| Geron Corporation | 394.07 Million USD | -646.647% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 23.174% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -698.49% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -1805.844% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -126.165% |
| Zoetis Inc. | 14.28 Billion USD | 79.404% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -400.2% |
| Abeona Therapeutics Inc. | 64 Million USD | -4497.289% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 87.055% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -5158.998% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 1.596% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 9.87% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -373.415% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -69.758% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -180.425% |
| Insmed Incorporated | 1.32 Billion USD | -121.257% |
| TG Therapeutics, Inc. | 329.58 Million USD | -792.741% |
| Incyte Corporation | 6.78 Billion USD | 56.616% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | -60.355% |